Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing

BACKGROUND: Since patients diagnosed with BRAF V600E and V600K mutated advanced melanoma show response to treatment with MAP kinase inhibitors, several sensitive methods have been developed to determine the V600 allele status of melanoma patients. Vemurafenib (Zelboraf) and dabrafenib (Tafinlar) are...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchant, Julie, Mange, Alain, Larrieux, Marion, Costes, Valérie, Solassol, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223712/
https://www.ncbi.nlm.nih.gov/pubmed/25037456
http://dx.doi.org/10.1186/1471-2407-14-519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223712/
https://www.ncbi.nlm.nih.gov/pubmed/25037456
http://dx.doi.org/10.1186/1471-2407-14-519

Ejemplares similares